Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-azacytidine Maintenance After Allo-HCT for High-risk AML/MDS
NCT02204020Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Apr 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Pittsburgh. Planned start Apr 2015; status: withdrawn.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02204020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204020.